Diabetes mellitus is a significant and growing health problem which contributes significantly to the prevalence of chronic kidney disease (CKD). According to the ERA-EDTA Registry, nearly a quarter (23 percent) of all patients who started renal replacement therapy in 2016 were patients with diabetes. The underlying idea of the study, which has been presented as a late breaking clinical trial at the ERA-EDTA congress in Budapest today, was to assess the potential of the DPP-4 inhibitor linagliptin (LINA), an oral diabetes drug, to reduce the burden of CKD and cardiac complications as secondary diseases in people with diabetes. Only a few weeks ago it had been shown that SGLT2 inhibitors, another class of diabetes drugs, could slow CKD progression in this patient group.
* This article was originally published here
Saturday, 15 June 2019
Microsoft gives glimpse of new Xbox console
Microsoft on Sunday gave the world a first glimpse of a powerful next-generation Xbox gaming console that it aims to release late next year.
* This article was originally published here
* This article was originally published here
UN says Ebola outbreak in Congo still not a global emergency
The World Health Organization on Friday said the Ebola outbreak in Congo—which spilled into Uganda this week—is an "extraordinary event" of deep concern but does not yet merit being declared a global emergency.
* This article was originally published here
* This article was originally published here
Dickkopf-related protein 3 (DKK3) predicts AKI
A new renal biomarker was presented at the ERA-EDTA Congress last year that shows that urinary DKK3 might help to identify patients who are at risk of progressive chronic kidney disease (CKD).
* This article was originally published here
* This article was originally published here
Subscribe to:
Posts (Atom)